Flavoxate

Summary

Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.

Flavoxate
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa682706
ATC code
Identifiers
  • 2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
CAS Number
  • 15301-69-6 checkY
PubChem CID
  • 3354
IUPHAR/BPS
  • 7187
DrugBank
  • DB01148 checkY
ChemSpider
  • 3237 checkY
UNII
  • 3E74Y80MEY
KEGG
  • D07961 checkY
ChEBI
  • CHEBI:5088 checkY
ChEMBL
  • ChEMBL1493 ☒N
CompTox Dashboard (EPA)
  • DTXSID3023053 Edit this at Wikidata
ECHA InfoCard100.035.745 Edit this at Wikidata
Chemical and physical data
FormulaC24H25NO4
Molar mass391.467 g·mol−1
3D model (JSmol)
  • Interactive image
  • O=C(OCCN1CCCCC1)c4cccc2c4O/C(=C(\C2=O)C)c3ccccc3
  • InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3 checkY
  • Key:SPIUTQOUKAMGCX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Clinical uses edit

Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin)(india), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon by Nippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.

Flavoxate is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Side effects edit

Flavoxate is generally well tolerated, but can potentially cause vomiting, upset stomach, dry mouth or throat, blurred vision, eye pain,[1] and increased sensitivity of the eyes to light.

Contraindications edit

Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

References edit

  1. ^ Mohammed ZS, Simi ZU, Tariq SM, Ali KR (November 2008). "Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate". British Journal of Clinical Pharmacology. 66 (5): 726–7. doi:10.1111/j.1365-2125.2008.03254.x. PMC 2661991. PMID 18754848.

Further reading edit

  • Brenner GN (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6.
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4.
  • "Flavoxate". PubMed Health. U.S. National Library of Medicine, National Institutes of Health.